# BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

> **NCT00796549** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BiBW 2992

## Key facts

- **NCT ID:** NCT00796549
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-05
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2014-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796549, "BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00796549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*